Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

Leukemia Research

Volumn 29, Issue 9, 2005, Pages 1003-1007

  Chevallier, Patrice ^a   Roland, Virginie ^a   Mahé, Béatrice ^a   Juge Morineau, Nadine ^a   Dubruille, Viviane ^a   Guillaume, Thierry ^a   Vigouroux, Stéphane ^a   Moreau, Philippe ^a   Milpied, Noël ^a   Garand, Richard ^a   Avet Loiseau, Herve ^a   Harousseau, Jean Luc ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

CD33; Intermediate dose cytarabine; Mitoxantrone; Mylotarg; Relapsed refractory AML

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BLAST CELL; BONE MARROW APLASIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; FEMALE; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LIVER TOXICITY; MALE; MULTIPLE ORGAN FAILURE; NEUTROPENIA; PRIORITY JOURNAL; RISK ASSESSMENT; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN OCCLUSION;

ACUTE DISEASE; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; HUMANS; LEUKEMIA, MYELOID; MITOXANTRONE; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 22144497190     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.02.005     Document Type: Article

References (20)

1. P.A. Dinndorf, R.G. Andrews, D. Benjamin, D. Ridgway, L. Wolff, and I.D. Berns Expression of normal myeloid associated antigens by acute leukemia cells Blood 67 1986 1048 1053
2. E.L. Sievers, R.A. Larson, E.A. Stadtmauer, E. Estey, B. Löwenberg, and H. Dombret Efficacy and safety of gemtuzumab ozogamicin in patients with CD33 positive acute myeloid leukemia in first relapse J Clin Oncol 19 2001 3244 3254
3. R.A. Larson Mylotarg Study Group Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia 16 9 2002 1627 1636
4. A.D. Cohen, S.M. Luger, C. Sickles, P.A. Mangan, D.L. Porter, and S.J. Schuster Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease Bone Marrow Transplant 30 1 2002 23 28
5. Y. Alvarado, A. Tsimberidou, H. Kantarjian, J. Cortes, G. Garcia-Manero, and S. Faderl Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia Cancer Chemother Pharmacol 51 2003 87 90
6. J. Cortes, A.M. Tsimberidou, R. Alvarez, D. Thomas, M. Beran, and H. Kantarjian Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia Cancer Chemother Pharmacol 50 2002 497 500
7. A. Tsimberidou, J. Cortes, D. Thomas, G. Garcia-Manero, S. Verstovsek, and S. Faderl Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia Leuk Res 27 2003 893 897
8. E. Apostolidou, J. Cortes, A. Tsimberidou, E. Estey, H. Kantarjian, and F.J. Giles Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia Leuk Res 27 2003 887 891
9. M. Attal, F. Huguet, H. Rubie, A. Huynh, J.P. Charlet, and J.L. Payen Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial Blood 79 11 1992 2834 2840
10. B. Löwenberg, J. Downing, and A. Burnett Acute myeloid leukemia, review article N Engl J Med 341 1999 1051 1062
11. W. Hiddemann, H. Kreutzmann, K. Straif, W.D. Ludwig, R. Mertelsmann, and R. Donhuijsen-Ant High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia Blood 69 1987 744 749
12. J.L. Harousseau, J. Reiffers, P. Hurteloup, N. Milpied, H. Guy, and F. Rigal-Huguet Treatment of relapsed acute myeloid leukemia with idarubicine and intermediate-dose cytarabine J Clin Oncol 7 1989 45 49
13. J.L. Harousseau, J. Reiffers, P. Hurteloup, N. Milpied, H. Guy, and F. Rigal-Huguet Treatment of relapsed acute myeloid leukemia with mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia Nouv Rev Fr Hematol 32 1990 227 230
14. D.W. Sternberg, W. Aird, D. Neuberg, L. Thompson, K. MacNeill, and P. Amrein Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen Cancer 88 9 2000 2037 2041
15. M.L. Linenberger, T. Hong, D. Flowers, E.L. Sievers, T.A. Gooley, and J.M. Bennett Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood 98 2001 988 994
16. R.B. Walter, B.W. Raden, T.C. Hong, D.A. Flowers, I.D. Bernstein, and M.L. Linenberger Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells Blood 102 2003 1466 1473
17. ®) treatment in acute myeloid leukemia patients Leukemia 18 5 2004 983 988
18. I. Jilani, E. Estey, Y. Huh, Y. Joe, T. Manshouri, and M. Yared Differences in CD33 intensity between various myeloid neoplasms Am J Clin Pathol 118 4 2002 560 566
19. G. Leone, S. Rutella, M.T. Voso, L. Fianchi, A. Scardocci, and L. Pagano In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study Haematologica 89 5 2004 634 636
20. I. Jedema, R.M. Barge, V.H. van der Velden, B.A. Nijmeijer, J.J. van Dongen, and R. Willemze Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity Leukemia 18 2 2004 316 325